Cite

    D.J. Pithadia et al.. “Dermatological adverse events associated with use of oral mechanistic target of rapamycin inhibitors in a cohort of individuals with tuberous sclerosis complex.” British journal of dermatology, vol. 183, 2020, pp. 588–589. http://access.bl.uk/ark:/81055/vdc_100172210133.0x000029